Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL9793607 | 0.95 | HTR1A (0.55) | SLC6A4HTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL9764443 | 0.90 | SLC6A4 (0.61) | SLC6A4 | |
| SCHEMBL4541937 | 0.88 | SLC6A4 (0.61) | SLC6A4 | |
| SCHEMBL9772971 | 0.84 | SLC6A4 (0.59) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL9772910 | 0.84 | SLC6A4 (0.59) | SLC6A4 | |
| SCHEMBL12015468 | 0.82 | HTR6 (0.45) | HTR1AHTR1DHTR1B | |
| SCHEMBL14207477 | 0.81 | SLC6A4 (0.53) | SLC6A4HTR1A | |
| SCHEMBL15292058 | 0.80 | SLC6A4 (0.60) | SLC6A4 | |
| SCHEMBL7809897 | 0.80 | SLC6A4 (0.69) | SLC6A4 | |
| SCHEMBL3379399 | 0.80 | SLC6A4 (0.71) | SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010004580-A2 | PROCESS FOR PREPARING INDOLE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | claimed |
| WO-2009016466-A2 | A PROCESS FOR THE PREPARATION OF NARATRIPTAN HYDROCHLORIDE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2009-02-05 | — | — | WO | claimed |
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | disclosed |
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| EP-2467373-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | Cipla Limited (IN) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| WO-2009016466-A2 | A PROCESS FOR THE PREPARATION OF NARATRIPTAN HYDROCHLORIDE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016466-A2 | A PROCESS FOR THE PREPARATION OF NARATRIPTAN HYDROCHLORIDE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008072257-A2 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008056378-A2 | NOVEL PROCESS FOR THE PREPARATION OF NARATRIPTAN HYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220778-A1 | Process for the synthesis of naratriptan | ZFR, SPR, NPSR1 | SLC6A4 32/4885HTR1A 318/4885HTR1D 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.